August 6, 2014— Sovaldi and other expensive new hepatitis C drugs will increase federal Medicare Part D spending by $2.9 billion to $5.8 billion in 2015 and raise Part D premiums by as much as 8.6 percent, pharmacy benefit management companies warn in a new report.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)